US20070264362A1 - Method and composition for treating ear inflammation caused by dry ear - Google Patents

Method and composition for treating ear inflammation caused by dry ear Download PDF

Info

Publication number
US20070264362A1
US20070264362A1 US11/432,656 US43265606A US2007264362A1 US 20070264362 A1 US20070264362 A1 US 20070264362A1 US 43265606 A US43265606 A US 43265606A US 2007264362 A1 US2007264362 A1 US 2007264362A1
Authority
US
United States
Prior art keywords
composition
ear
agent
wound healing
irritant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/432,656
Inventor
Nina Yoshpe
Ayal Willner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/432,656 priority Critical patent/US20070264362A1/en
Publication of US20070264362A1 publication Critical patent/US20070264362A1/en
Priority to US12/189,501 priority patent/US7879372B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/76Salicaceae (Willow family), e.g. poplar
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/886Aloeaceae (Aloe family), e.g. aloe vera

Definitions

  • This invention relates to the treatment of inflammation of the inner ear of a mammal, e.g. humans or pets, caused by histosis, which treatment comprises topical application of a liquid composition to the inflamed tissue.
  • Alcohol is commonly used to clean out the ear, especially of pets, because it dissolves the natural oils and fats present in the ear, but alcohol is also irritating, especially if the ear is presented with lesions or is inflamed. Alcohol evaporates quickly, thereby often over-drying the ear and leaving it red and irritated.
  • Hydrogen peroxide is also often used to clean pet ears, but it does not dissolve the waxes and oils and does not kill infections as well as does alcohol, although it is usually mild enough such as not to irritate the ear.
  • acetic acid and water or acetic acid and alcohol. While such mixtures are effective in killing bacteria and in eliminating yeast infections, they are not pH balanced and may irritate or actually burn the ear if the pH is too low. Additionally, the acetic acid/alcohol mixture has a tendency to over-dry the ear.
  • Asteatosis is a common condition of the external auditory canal where the skin surface in the canal is dry and lacks cerumen production. This condition is sometimes associated with aging. Because of the lack of cerumen which is protective of the canal, there is a change in the ph of the canal which may make it more prone to external ear infection. The dryness of the canal skin leads to itching and subsequent scratching and irritation of the canal. It is at this point that many patients will insert cotton tip applicators and other foreign bodies in the canal to alleviate the discomfort. Because there is not cerumen in the canal pathogenic and nonpathogenic bacteria and fungi may dominate the flora of the canal, cause overgrowth and actual infection. These infections can often time be very difficult to clear up requiring multiple office visits, particularly if these is fungal overgrowth.
  • the ear canal may be over-dry as a result of aging, cleaning or for other reasons.
  • the present invention provides a method and composition for treating ear inflammation caused by dry ear.
  • the compositions of this invention utilizes as active ingredients, compounds that are derived from natural as opposed to synthetic ingredients.
  • the present invention provides a method and composition for treating ear inflammation caused by dry ear or histosis.
  • Said composition comprises a mixture of natural products having anti-inflammatory, anti-irritant, and wound healing properties in a polyhydroxy solvent.
  • composition of the present invention has emollient and lubrication properties and is topically applied as ear drops to the ear of a patient to treat histosis or dry ear or the conditions resulting therefrom or associated therewith.
  • the novel composition used in the method of the present invention comprises a natural anti-irritant dissolved in polyhydroxy organic solvent.
  • said natural anti-irritant may comprise an avenanthramide, such as an oat (Avena Sativa) Kernel extract.
  • the polyhydroxy solvent may be a glycol or a glycerine compound, e.g. a mixture of two or more glycols compounds or glycerines.
  • composition of this invention may further comprise a compound having wound healing activity.
  • Alpha bisbolol i.e., (+)-epi-bisabolol the wound healing principle of Peperomia galioides may be included in the compositions of the present invention.
  • Alpha bisbolol is also known as a soothing agent.
  • composition of this invention may further include an emollient, such as Aloe, which reduces irritation and treats abrasions, minor wounds, and burns.
  • an emollient such as Aloe, which reduces irritation and treats abrasions, minor wounds, and burns.
  • compositions of this invention also may include a pain reliever such as a White Willow Bark extract which also has anti-inflammatory properties.
  • compositions may comprise a humectant, e.g. a pyrrolidone carboxylic acid.
  • a compound having anti-allergy properties may be incorporated in the compositions of the present invention, e.g. a liquorice root extract such as dipotasium glycyrrhizate, which has anti-allergic properties, but also is an anti-inflammatory agent and a surfactant.
  • a liquorice root extract such as dipotasium glycyrrhizate, which has anti-allergic properties, but also is an anti-inflammatory agent and a surfactant.
  • the present invention preferably comprises a mixture of natural products having anti-inflammatory, anti-irritant and wound healing properties, (hereinafter “active ingredients”) in a polyhydroxy solvent wherein said solvent is a mixture of one or more glycol compounds or dihuydric alcohol compounds and one or more glycerin compounds, or trihydric alcohol compounds e.g. a diglycerine.
  • active ingredients natural products having anti-inflammatory, anti-irritant and wound healing properties
  • the active ingredients may comprise from about 0.5 to about 10%, by weight, of said ear drop composition. More preferably, said active ingredients may comprise from about 0.75 to about 5%, by weight, e.g. from about 1 to about 3%, by weight, of said ear drop composition.
  • the glycol compounds may comprise dihydroxyalkyl compounds, such as 1,3 butylenegylcol, ethylene glycol, 1,2 propylene glycol or hydroxyalkyloxyalkyl compounds such hydroxymethyleneoxyethylene glycol, etc.
  • dihydroxyalkyl compounds such as 1,3 butylenegylcol, ethylene glycol, 1,2 propylene glycol or hydroxyalkyloxyalkyl compounds such hydroxymethyleneoxyethylene glycol, etc.
  • said glycol is 1,3 butyleneglycol, which besides having the necessary solvent properties provides anti-fungal and anti-bacterial properties.
  • the glycerin compound or trihydric alcohol may comprise glycerin from natural or synthetic sources, preferably from natural sources.
  • glycerin provides emollient, humectant, and lubrication properties to the present compositions.
  • the active ingredients preferably are as follows:
  • An anti-irritant agent derived from a natural source e.g. an avenanthramide wherein m is an integer, e.g. of from 1 to 4, i.e. 1, 2 or 3.
  • a preferred avenanthramide source is a product sold as Drago-Calm available from Syrmise of Teterboro, New Jersey, 00768.
  • Drago-Calm is reported to be an Oat (Avena Satvia) Kernel Extract having a guaranteed active constituent concentration of 100 ppm avenanthramides
  • the Avenanthramides include in this product are analogues of TranilastTM, which is a potent anti-histamine
  • the anti-irritant agent may comprise from about 0.1 to about 5%, by weight, preferably from 0.5 to about 1.5%, by weight, of the eardrop composition of this invention.
  • composition of this invention may further comprise one or more compounds having natural wound healing activity.
  • said wound healing compounds may comprise Aloe and/or alpha-bisbolol.
  • Aloe is a gel obtained by crushing the mucilaginous cells found in the inner tissue of the plant leaf. Aloe is a wound healing agent and has emollient properties. The emollient effect of this gel is largely attributed to a constituent polysaccharide (glucomannan) similar to guar gum.
  • the term “aloe” refers to a solid residue obtained by evaporating the latex derived from the outer layers of the plant leaf. Aloe latex also contains the anthraquinone barbaloin (a glucoside of aloe-emodin).
  • Topical application of aloe in the compositions of this invention alleviates irritation, inhibit infection and promote healing of abrasions, minor wounds, and bums.
  • aloe gel in relieving skin irritation in dry ear may be due, in part, to its moisturizing activity which reduces drying of abraded or injured skin.
  • Aloe also has anti-inflammatory properties.
  • Alpha bisabolol or (+) epi-Alpha-bisobolol is a terpenoid which is the wound healing principal of Peperomia galioides and also has anti-inflammatory properties. Natural Alpha bisabolol is available from BASF.
  • the wound healing components of the present eardrop compositions, i.e. aloe and/or alpha bisabolol may comprise from about 0.01 to about 1%, by weight, preferably from about 0.05 to about 0.15%, by weight.
  • compositions of the present invention preferably may comprise further anti-inflammatory agents, which agents may, in addition, have anti-allergy and analgesic properties such as salts of glycyrrhic acid, e.g. dipotassium glycyrrhizate and White Willow Bark extract, respectively.
  • agents may, in addition, have anti-allergy and analgesic properties such as salts of glycyrrhic acid, e.g. dipotassium glycyrrhizate and White Willow Bark extract, respectively.
  • the dipotassium glycyrrhizate may be extracted from liquorice root.
  • the bark of the white willow tree is a source of salicin and other salicylic—compounds which are similar in structure to aspirin (acetyl salicylic acid) Native Americans are thought to have used ground willow bark a as a medicinal remedy for everything from pain relief to fevers.
  • white willow bark is often used as a natural alternative aspirin—one of the most common uses in dietary supplements is as a adjunct for weight loss.
  • the extract of white willow tree bark is utilized in the present compositions as a pain reliever (headaches, arthritis, minor injuries) and an anti-inflammatory agent.
  • the primary active compound in white willow bark is salicin.
  • salicin can be converted into salicylic acid, which has powerful effects as an anti-inflammatory and pain reliever.
  • the anti-inflammatory agents may comprise from about 0.001 to about 1%, by weight of the compositions of this invention, e.g. from about 0.002 to about 0.05%, by weight, of such compositions.
  • compositions of the present invention may further comprise additional humectants in addition to glycerin discussed above.
  • the ear drop composition will comprise a natural humectant such as pyrrolidone carboxylic acid, such as Ajidew N-50 which is the sodium salt of said acid and is available from Ajinomoto USA, Inc. of Paramus, N.J. 07652.
  • a natural humectant such as pyrrolidone carboxylic acid, such as Ajidew N-50 which is the sodium salt of said acid and is available from Ajinomoto USA, Inc. of Paramus, N.J. 07652.
  • compositions of the present invention may include one or more surfactants to stabilize the compositions.
  • At least one of the surfactants is a cationic surfactant, e.g. a quatenary amine, such as Stepanquat 50 NF which is a dialkyl dimethylammonium chloride and is available from Stepan Company.
  • a cationic surfactant e.g. a quatenary amine, such as Stepanquat 50 NF which is a dialkyl dimethylammonium chloride and is available from Stepan Company.
  • the cationic surfactant stabilized compositions additionally include a nonionic surfactant such as Tween 20.
  • the surfactants may comprise from about 0.02 to about 1% by weight of said compositions, more preferably from about 0.2 to about 0.45% by weight.
  • composition discloses a preferred embodiment of this invention and the sources of the individual components.
  • TABLE Percentage Formula % By Weight Weight Range 1,3-Butylene Glycol 47.8300% 40-50 Diglycerine 801 50.0000 40-50 Dragocalm #2/060910 1.0000 0.5-1.5 Ajidew N-50 0.5000 0.25-0.75 ABS White Willow Bar Extract, powder 0.0100 .005-.015 OriStar DPG 0.2000 0.1-0.25 Stepanquat 50 NF 0.1000 0.05-0.15 Alpha-Bisbolol, natural 0.1000 0.05-0.15 Tween 20 0.2500 0.15-0.30 ActivAloe, #AA1210A 0.0100 0.005-.015 100.0000%
  • composition is prepared as disclosed below.
  • Compounding Formula Batch Size 1,000 lbs. By Weight Part A 1,3-Butylene Glycol 458.3000 lbs.
  • Diglycerine 801 500.000 Drgocalm #2/060910 10.000 Ajidew N-50 5.000 Part B 1,3-Butylene Glycol 20.000 ABS White Willow Bark Extract, powder 0.1000 OriStar DPG 2.0000 Stepanquat 50 NF 1.0000 Alpha-Bisbolol, natural 1.0000 Tween 20 2.5000 ActivAloe, #AA1210A 0.1000 1,000.0000 lbs.
  • Part A Add Butylene Glycol into the main processing tank. Add the remaining Part A ingredients. Mix until uniform. Part B In a separate tank, heat Part B ingredients to 45° C. Mix until all the solids are dissolved and the batch is uniform. Add Part B to Part A. Mix until uniform. Sample for QC check.
  • DD is a 56 Caucasian female who has had recurrent external ear infections. She has been treated with various antibacterial and antifungal preparations. After finally getting the infections cleared, she has had no cerumen production in the external canal. With the use of the emollient and lubricating drops, she has successfully remained infection free for greater than six months while continuing her water activity.
  • AH is a 12 year old asian American female with sensorineural hearing loss with a history of very dry ear canals and external ear infections. Despite multiple medications it was difficult to clear her ear canals for long periods of time so that she could wear her hearing aid. Once the infections had cleared with the use of the, emollient and lubricating drops, she has been able to successfully wear her hearing aids and follow up visits only every three months.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method of treating diseases and conditions associated with dry ear comprising topically applying to the ear canal of a subject that is suffering therefrom a liquid composition comprising an anti-irritant agent, a wound healing agent; and an anti-inflammatory agent dissolved in a polyhydroxy liquid solvent.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention relates to the treatment of inflammation of the inner ear of a mammal, e.g. humans or pets, caused by asteatosis, which treatment comprises topical application of a liquid composition to the inflamed tissue.
  • 2. Related Art
  • It is well known that a moist environment in the inner ear of a human or a pet can result in various diseases such as Swimmer's Ear. Swimmer's Ear is an example of a common affectation of the ear caused by excessive moisture whereby a swimmer receives contaminated water in the ear or overly moisturizes the ear causing it to succumb to microbial growth (most often pseudomonas). Thus, there are many compositions that are disclosed for use in removing water from and drying the ear canal.
  • Alcohol is commonly used to clean out the ear, especially of pets, because it dissolves the natural oils and fats present in the ear, but alcohol is also irritating, especially if the ear is presented with lesions or is inflamed. Alcohol evaporates quickly, thereby often over-drying the ear and leaving it red and irritated.
  • Hydrogen peroxide is also often used to clean pet ears, but it does not dissolve the waxes and oils and does not kill infections as well as does alcohol, although it is usually mild enough such as not to irritate the ear.
  • Also commonly used to clean pet ears is a mixture of acetic acid and water, or acetic acid and alcohol. While such mixtures are effective in killing bacteria and in eliminating yeast infections, they are not pH balanced and may irritate or actually burn the ear if the pH is too low. Additionally, the acetic acid/alcohol mixture has a tendency to over-dry the ear.
  • Many people clean their ears and/or the ears of their pets with Q-tips. This procedure can cause dry ear by stripping the protective coating of earwax that protects the skin lining of the ear canal. As a result, the ear canal may suffer from atopic dermatitis or even more serious a skin infection (otitus externa) can develop in the ear canal
  • Asteatosis is a common condition of the external auditory canal where the skin surface in the canal is dry and lacks cerumen production. This condition is sometimes associated with aging. Because of the lack of cerumen which is protective of the canal, there is a change in the ph of the canal which may make it more prone to external ear infection. The dryness of the canal skin leads to itching and subsequent scratching and irritation of the canal. It is at this point that many patients will insert cotton tip applicators and other foreign bodies in the canal to alleviate the discomfort. Because there is not cerumen in the canal pathogenic and nonpathogenic bacteria and fungi may dominate the flora of the canal, cause overgrowth and actual infection. These infections can often time be very difficult to clear up requiring multiple office visits, particularly if these is fungal overgrowth.
  • Thus, in many instances the ear canal may be over-dry as a result of aging, cleaning or for other reasons.
  • The problem with over drying the ear canal is that serious diseases or conditions, e.g. inflammation, may be the result.
  • The present invention provides a method and composition for treating ear inflammation caused by dry ear. The compositions of this invention utilizes as active ingredients, compounds that are derived from natural as opposed to synthetic ingredients.
  • BRIEF SUMMARY OF THE INVENTION
  • The present invention provides a method and composition for treating ear inflammation caused by dry ear or asteatosis. Said composition comprises a mixture of natural products having anti-inflammatory, anti-irritant, and wound healing properties in a polyhydroxy solvent.
  • The composition of the present invention has emollient and lubrication properties and is topically applied as ear drops to the ear of a patient to treat asteatosis or dry ear or the conditions resulting therefrom or associated therewith.
  • The novel composition used in the method of the present invention comprises a natural anti-irritant dissolved in polyhydroxy organic solvent. For example, said natural anti-irritant may comprise an avenanthramide, such as an oat (Avena Sativa) Kernel extract.
  • The polyhydroxy solvent may be a glycol or a glycerine compound, e.g. a mixture of two or more glycols compounds or glycerines.
  • The composition of this invention may further comprise a compound having wound healing activity. For example, Alpha bisbolol, i.e., (+)-epi-bisabolol the wound healing principle of Peperomia galioides may be included in the compositions of the present invention. Alpha bisbolol is also known as a soothing agent.
  • The composition of this invention may further include an emollient, such as Aloe, which reduces irritation and treats abrasions, minor wounds, and burns.
  • The compositions of this invention also may include a pain reliever such as a White Willow Bark extract which also has anti-inflammatory properties.
  • Furthermore, the present compositions may comprise a humectant, e.g. a pyrrolidone carboxylic acid.
  • Finally, a compound having anti-allergy properties may be incorporated in the compositions of the present invention, e.g. a liquorice root extract such as dipotasium glycyrrhizate, which has anti-allergic properties, but also is an anti-inflammatory agent and a surfactant.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention preferably comprises a mixture of natural products having anti-inflammatory, anti-irritant and wound healing properties, (hereinafter “active ingredients”) in a polyhydroxy solvent wherein said solvent is a mixture of one or more glycol compounds or dihuydric alcohol compounds and one or more glycerin compounds, or trihydric alcohol compounds e.g. a diglycerine.
  • The active ingredients may comprise from about 0.5 to about 10%, by weight, of said ear drop composition. More preferably, said active ingredients may comprise from about 0.75 to about 5%, by weight, e.g. from about 1 to about 3%, by weight, of said ear drop composition.
  • The glycol compounds may comprise dihydroxyalkyl compounds, such as 1,3 butylenegylcol, ethylene glycol, 1,2 propylene glycol or hydroxyalkyloxyalkyl compounds such hydroxymethyleneoxyethylene glycol, etc. Most preferably, said glycol is 1,3 butyleneglycol, which besides having the necessary solvent properties provides anti-fungal and anti-bacterial properties.
  • The glycerin compound or trihydric alcohol may comprise glycerin from natural or synthetic sources, preferably from natural sources.
  • In addition, to functioning as a solvent in the eardrop compositions of this invention glycerin provides emollient, humectant, and lubrication properties to the present compositions.
  • The active ingredients preferably are as follows:
  • An anti-irritant agent derived from a natural source, e.g. an avenanthramide
    Figure US20070264362A1-20071115-C00001

    wherein m is an integer, e.g. of from 1 to 4, i.e. 1, 2 or 3.
  • A preferred avenanthramide source is a product sold as Drago-Calm available from Syrmise of Teterboro, New Jersey, 00768.
  • Drago-Calm is reported to be an Oat (Avena Satvia) Kernel Extract having a guaranteed active constituent concentration of 100 ppm avenanthramides
  • This product has superior anti-irritant and anti-oxidant properties. The Avenanthramides include in this product are analogues of Tranilast™, which is a potent anti-histamine
  • The anti-irritant agent may comprise from about 0.1 to about 5%, by weight, preferably from 0.5 to about 1.5%, by weight, of the eardrop composition of this invention.
  • The composition of this invention may further comprise one or more compounds having natural wound healing activity. Preferably, said wound healing compounds may comprise Aloe and/or alpha-bisbolol.
  • Aloe is a gel obtained by crushing the mucilaginous cells found in the inner tissue of the plant leaf. Aloe is a wound healing agent and has emollient properties. The emollient effect of this gel is largely attributed to a constituent polysaccharide (glucomannan) similar to guar gum. The term “aloe” refers to a solid residue obtained by evaporating the latex derived from the outer layers of the plant leaf. Aloe latex also contains the anthraquinone barbaloin (a glucoside of aloe-emodin).
  • Topical application of aloe in the compositions of this invention alleviates irritation, inhibit infection and promote healing of abrasions, minor wounds, and bums.
  • The beneficial effects of aloe gel in relieving skin irritation in dry ear may be due, in part, to its moisturizing activity which reduces drying of abraded or injured skin. Some clinical studies have demonstrated acceleration of wound healing from aloe.
  • Aloe also has anti-inflammatory properties.
  • Alpha bisabolol or (+) epi-Alpha-bisobolol is a terpenoid which is the wound healing principal of Peperomia galioides and also has anti-inflammatory properties. Natural Alpha bisabolol is available from BASF. The wound healing components of the present eardrop compositions, i.e. aloe and/or alpha bisabolol, may comprise from about 0.01 to about 1%, by weight, preferably from about 0.05 to about 0.15%, by weight.
  • The compositions of the present invention preferably may comprise further anti-inflammatory agents, which agents may, in addition, have anti-allergy and analgesic properties such as salts of glycyrrhic acid, e.g. dipotassium glycyrrhizate and White Willow Bark extract, respectively.
  • The dipotassium glycyrrhizate may be extracted from liquorice root.
  • The bark of the white willow tree is a source of salicin and other salicylic—compounds which are similar in structure to aspirin (acetyl salicylic acid) Native Americans are thought to have used ground willow bark a as a medicinal remedy for everything from pain relief to fevers. Today, white willow bark is often used as a natural alternative aspirin—one of the most common uses in dietary supplements is as a adjunct for weight loss.
  • Thus, the extract of white willow tree bark is utilized in the present compositions as a pain reliever (headaches, arthritis, minor injuries) and an anti-inflammatory agent.
  • The primary active compound in white willow bark is salicin. In the body salicin can be converted into salicylic acid, which has powerful effects as an anti-inflammatory and pain reliever.
  • The anti-inflammatory agents may comprise from about 0.001 to about 1%, by weight of the compositions of this invention, e.g. from about 0.002 to about 0.05%, by weight, of such compositions.
  • The compositions of the present invention may further comprise additional humectants in addition to glycerin discussed above.
  • Preferably, the ear drop composition will comprise a natural humectant such as pyrrolidone carboxylic acid, such as Ajidew N-50 which is the sodium salt of said acid and is available from Ajinomoto USA, Inc. of Paramus, N.J. 07652.
  • Finally, the compositions of the present invention may include one or more surfactants to stabilize the compositions.
  • Preferably, at least one of the surfactants is a cationic surfactant, e.g. a quatenary amine, such as Stepanquat 50 NF which is a dialkyl dimethylammonium chloride and is available from Stepan Company.
  • More preferably, the cationic surfactant stabilized compositions additionally include a nonionic surfactant such as Tween 20.
  • The surfactants may comprise from about 0.02 to about 1% by weight of said compositions, more preferably from about 0.2 to about 0.45% by weight.
  • The composition below discloses a preferred embodiment of this invention and the sources of the individual components.
    TABLE
    Percentage Formula
    % By Weight Weight Range
    1,3-Butylene Glycol 47.8300% 40-50
    Diglycerine 801 50.0000 40-50
    Dragocalm #2/060910 1.0000 0.5-1.5
    Ajidew N-50 0.5000 0.25-0.75
    ABS White Willow Bar Extract, powder 0.0100 .005-.015
    OriStar DPG 0.2000  0.1-0.25
    Stepanquat 50 NF 0.1000 0.05-0.15
    Alpha-Bisbolol, natural 0.1000 0.05-0.15
    Tween 20 0.2500 0.15-0.30
    ActivAloe, #AA1210A 0.0100 0.005-.015 
    100.0000%
  • The preferred composition is prepared as disclosed below.
    Compounding Formula
    Batch Size: 1,000 lbs.
    By Weight
    Part A 1,3-Butylene Glycol 458.3000 lbs.
    Diglycerine 801 500.000
    Drgocalm #2/060910 10.000
    Ajidew N-50 5.000
    Part B 1,3-Butylene Glycol 20.000
    ABS White Willow Bark Extract, powder 0.1000
    OriStar DPG 2.0000
    Stepanquat 50 NF 1.0000
    Alpha-Bisbolol, natural 1.0000
    Tween 20 2.5000
    ActivAloe, #AA1210A 0.1000
    1,000.0000 lbs.
  • TABLE
    Compounding Procedure
    Part A Add Butylene Glycol into the main processing tank.
    Add the remaining Part A ingredients. Mix until uniform.
    Part B In a separate tank, heat Part B ingredients to 45° C.
    Mix until all the solids are dissolved and the batch is uniform.
    Add Part B to Part A. Mix until uniform. Sample for QC check.
  • EXAMPLES
  • 1. DD is a 56 Caucasian female who has had recurrent external ear infections. She has been treated with various antibacterial and antifungal preparations. After finally getting the infections cleared, she has had no cerumen production in the external canal. With the use of the emollient and lubricating drops, she has successfully remained infection free for greater than six months while continuing her water activity.
  • 2. AH is a 12 year old asian American female with sensorineural hearing loss with a history of very dry ear canals and external ear infections. Despite multiple medications it was difficult to clear her ear canals for long periods of time so that she could wear her hearing aid. Once the infections had cleared with the use of the, emollient and lubricating drops, she has been able to successfully wear her hearing aids and follow up visits only every three months.

Claims (21)

1. A method of treating diseases and conditions associated with dry ear or asteatosis which comprises topically applying to the ear canal of a subject that is suffering therefrom a liquid composition comprising:
(a) an anti-irritant agent;
(b) a wound healing agent; and
(c) an anti-inflammatory agent:
dissolved in a polyhydroxy liquid solvent.
2. The method of claim 1 wherein said subject is a human.
3. The method of claim 1 wherein said polyhydroxy solvent is a mixture of a glycol and a glycerin.
4. The method of claim 3 wherein said polyhydroxy solvent is a mixture of butylene glycol and glycerin.
5. The method of claim 1 wherein anti-irritant is an avenanthramide.
6. The method of claim 1 wherein wound healing agent is selected from the group consisting of Aloe, alphabisolol, and a mixture thereof.
7. The method of claim 1 wherein anti-inflammatory agent is selected from the group consisting of dipotassium glycyrrhizate and White Willow Bark Extract.
8. The method of claim 1 wherein said composition further comprises a cationic surfactant.
9. The method of claim 8 wherein said composition further comprises from about 0.5 to about 10%, by weight, of said agents (a), (b), and (c).
10. The method of claim 1 wherein said liquid composition comprises from about 0.1 to about 5% of an anti-irritant agent, 0.01 to about 1% of a wound healing agent and 0.001 to about 1% of an anti-inflammatory agent.
11. A composition for treating the diseases and conditions associated with dry ear which comprises;
(a) an anti-irritant agent;
(b) a wound healing agent; and
(c) an anti-inflammatory agent:
dissolved in a polyhydroxy liquid solvent.
12. The composition of claim 11 wherein said subject is a human.
13. The composition of claim 11 wherein said polyhydroxy solvent is a mixture of a glycol and a glycerin.
14. The composition of claim 13 wherein said polyhydroxy solvent is a mixture of butylene glycol and glycerin.
15. The composition of claim 11 wherein anti-irritant is an avenanthramide.
16. The composition of claim 11 wherein wound healing agent is selected from the group consisting of Aloe, alphabisolol and a mixture thereof.
17. The composition of claim 11 wherein anti-inflammatory agent is selected from the group consisting of dipotassium glycyrrhizate and White Willow Bark Extract.
18. The composition of claim 11 wherein said composition further comprises a cationic surfactant.
19. The composition of claim 18 wherein said composition further comprises from about 0.5 to about 10%, by weight, of said agents (a), (b), and (c).
20. The composition of claim 11 wherein said liquid composition comprises
21. The method of claim 1 wherein said liquid composition comprises from about 0.1 to about 5% of an anti-irritant agent, 0.01 to about 1% of a wound healing agent and 0.001 to about 1% of an anti-inflammatory agent.
US11/432,656 2006-05-11 2006-05-11 Method and composition for treating ear inflammation caused by dry ear Abandoned US20070264362A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/432,656 US20070264362A1 (en) 2006-05-11 2006-05-11 Method and composition for treating ear inflammation caused by dry ear
US12/189,501 US7879372B2 (en) 2006-05-11 2008-08-11 Method and composition for treating ear inflammation caused by dry ear

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/432,656 US20070264362A1 (en) 2006-05-11 2006-05-11 Method and composition for treating ear inflammation caused by dry ear

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/189,501 Continuation US7879372B2 (en) 2006-05-11 2008-08-11 Method and composition for treating ear inflammation caused by dry ear

Publications (1)

Publication Number Publication Date
US20070264362A1 true US20070264362A1 (en) 2007-11-15

Family

ID=38685442

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/432,656 Abandoned US20070264362A1 (en) 2006-05-11 2006-05-11 Method and composition for treating ear inflammation caused by dry ear
US12/189,501 Active 2026-08-27 US7879372B2 (en) 2006-05-11 2008-08-11 Method and composition for treating ear inflammation caused by dry ear

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/189,501 Active 2026-08-27 US7879372B2 (en) 2006-05-11 2008-08-11 Method and composition for treating ear inflammation caused by dry ear

Country Status (1)

Country Link
US (2) US20070264362A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064911A1 (en) * 2011-09-09 2013-03-14 Nina S. YOSHPE Method and formulation for treating dry ear inflammation with cortisone
US9498420B2 (en) 2013-05-01 2016-11-22 The Procter & Gamble Company Cosmetic compositions and methods for inhibiting melanin synthesis
US9757317B2 (en) 2014-09-12 2017-09-12 The Procter & Gamble Company Cosmetic compositions and methods for inhibiting melanin synthesis
US20180360100A1 (en) * 2017-06-13 2018-12-20 Scientific Holdings, Llc Unexpectedly Enhanced Pigments Compositions and Processes
CN111821381A (en) * 2020-08-25 2020-10-27 东晟源研究院(广州)有限公司 Cat ear care water containing traditional Chinese medicine composition and preparation method thereof
WO2021175454A1 (en) * 2020-03-06 2021-09-10 Symrise Ag Avenanthramide compositions with improved solubility comprising 4-hydroxyphenone

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
FR2987745B1 (en) * 2012-03-07 2014-04-11 Gilbert Lab HEALTH CARE HEALTH AND CARE COMPOSITION
JP6734781B2 (en) 2014-03-14 2020-08-05 ゴジョ・インダストリーズ・インコーポレイテッド Hand sanitizer with improved aesthetics and skin conditioning to encourage adherence to hand hygiene guidelines

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025620A (en) * 1975-10-22 1977-05-24 Leo Pharmaceutical Products Ltd., A/S Treatment of canine otitis and composition therefor
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4938959A (en) * 1984-11-14 1990-07-03 Georges Serge Grimberg Insoluble medicament for a local administration in a human or animal ear
US5480658A (en) * 1993-07-23 1996-01-02 Melman; Steven A. Ear and skin cleanser
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
US20040101506A1 (en) * 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US6818232B1 (en) * 1999-05-06 2004-11-16 Ceapro, Inc. Oat extracts: refining, compositions and methods of use
US6844014B1 (en) * 2002-07-22 2005-01-18 Stephen Rafkin Herbal healing lotion for veterinary use
US20060045892A1 (en) * 2004-08-25 2006-03-02 Piotr Chomczynski Cosmetic compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085800B2 (en) * 1986-12-19 1996-01-24 エーザイ株式会社 Aqueous formulation containing lysozyme chloride and dipotassium glycyrrhizinate

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025620A (en) * 1975-10-22 1977-05-24 Leo Pharmaceutical Products Ltd., A/S Treatment of canine otitis and composition therefor
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4938959A (en) * 1984-11-14 1990-07-03 Georges Serge Grimberg Insoluble medicament for a local administration in a human or animal ear
US5480658A (en) * 1993-07-23 1996-01-02 Melman; Steven A. Ear and skin cleanser
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
US6818232B1 (en) * 1999-05-06 2004-11-16 Ceapro, Inc. Oat extracts: refining, compositions and methods of use
US6844014B1 (en) * 2002-07-22 2005-01-18 Stephen Rafkin Herbal healing lotion for veterinary use
US20040101506A1 (en) * 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US20060045892A1 (en) * 2004-08-25 2006-03-02 Piotr Chomczynski Cosmetic compositions

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064911A1 (en) * 2011-09-09 2013-03-14 Nina S. YOSHPE Method and formulation for treating dry ear inflammation with cortisone
US8758836B2 (en) * 2011-09-09 2014-06-24 Nina S. YOSHPE Method and formulation for treating dry ear inflammation with cortisone
US9498420B2 (en) 2013-05-01 2016-11-22 The Procter & Gamble Company Cosmetic compositions and methods for inhibiting melanin synthesis
US9757317B2 (en) 2014-09-12 2017-09-12 The Procter & Gamble Company Cosmetic compositions and methods for inhibiting melanin synthesis
US20180360100A1 (en) * 2017-06-13 2018-12-20 Scientific Holdings, Llc Unexpectedly Enhanced Pigments Compositions and Processes
WO2021175454A1 (en) * 2020-03-06 2021-09-10 Symrise Ag Avenanthramide compositions with improved solubility comprising 4-hydroxyphenone
CN115243669A (en) * 2020-03-06 2022-10-25 西姆莱斯股份公司 Avenanthramide compositions with enhanced solubility comprising 4-hydroxybenzophenones
CN111821381A (en) * 2020-08-25 2020-10-27 东晟源研究院(广州)有限公司 Cat ear care water containing traditional Chinese medicine composition and preparation method thereof

Also Published As

Publication number Publication date
US20080299233A1 (en) 2008-12-04
US7879372B2 (en) 2011-02-01

Similar Documents

Publication Publication Date Title
US7879372B2 (en) Method and composition for treating ear inflammation caused by dry ear
US12083085B2 (en) Antiseptic, antiseborrheic, exfoliating composition to remove or prevent acne
JP2003515615A (en) Antimicrobial composition for treatment
KR100828656B1 (en) Periodontal disease therapeutic and/or preventive composition
CN109431873B (en) Composition for repairing and relieving skin inflammation
WO2008140200A1 (en) External compositions for the skin
CN111789798A (en) Bactericide containing aloe extract and preparation method thereof
CN104800099B (en) Skin cleaning agent and preparation method thereof
HUE026862T2 (en) Combined plant extracts for use in the treatment of microbial infections
CN107405302B (en) Composition for topical application in the ear canal
KR102148808B1 (en) Feminine Cleanser Composition Comprising Natural Antimicrobial Agents
DE102008036725B4 (en) Pharmaceutical composition for nasal application
KR100682979B1 (en) Composition for precaution treatment having synergism for antimicrobial infection and antiinflammatory action and treatment for athletes foot provided by using them
US8758836B2 (en) Method and formulation for treating dry ear inflammation with cortisone
KR101418366B1 (en) Composition containing bee venom and propolis for preventing or treating acne
CN108451799A (en) A kind of hand cleanser and preparation method thereof
US8486459B2 (en) Bulbine frutescens extract
KR102475898B1 (en) Cosmetic composition comprising Graviola antibiotic extract and method of preparing the same
KR101841976B1 (en) Antifungal and antibacterial composition comprising herbal extract
KR102228690B1 (en) Hypoallergenic vulvar cleaner composition that helps with excellent antibacterial effect and itchiness relief
KR20100117261A (en) Composite of shampoo
CN113413331B (en) Acne-removing composition and preparation and application thereof
KR20090071529A (en) Cosmetic composition comprising vitamin k1 or vitamin k3 for anti-bacterial and anti-fungal bio-activity
KR20170094609A (en) Manufactureing method of periodontitis prevention solution
Indrastiti et al. The Effectiveness of Moringa Oleifera Lam Extract as an Oral Antimicrobial: a Systematic Literature Review

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION